Drugs / prifetrastat
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07335419 | Jan → Feb 2026 overdue | — | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07423286 | Oct → Dec 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07198035 | Sep → Dec 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07636018 | Aug → Oct 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07117799 | Feb → Jun 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT07340619 | May 2026 → Nov 2028 expected | metastatic melanoma | UNICANCER | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04606446 | Nov 2020 → Jul 2029 expected | breast cancer, castration-resistant prostate carcinoma, non-small cell lung carcinoma | Pfizer | Recruiting | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT07062965 | Aug 2025 → Jul 2027 expected | breast cancer | Pfizer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-23 | Pfizer | Results Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting pfizer.com ↗
These results support the recommended dosing for PF-07248144 ahead of the Phase 3 trial initiation in second-line mBC planned for 2H 2025. |
| 2024-12-05 | Pfizer | Results Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS pfizer.com ↗ |
All press releases naming this drug 2 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | prifetrastat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07340619 ↗ |
| Known as | PF-07248144 | “A new drug, prifetrastat (PF-07248144), which targets KAT6 proteins, which play a role in the growth of cancer cells, has shown promising results.” NCT07340619 ↗ |
| Action | Inhibit | “PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B.” PMID 38824244 ↗ Jun 2024 |
| Modality | Small molecule | — CHEMBL6068620 ↗ |
| Route | Oral | “taken by mouth” NCT07062965 ↗ |
| Target | KAT6A | “PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B.” PMID 38824244 ↗ Jun 2024 |
| Target | KAT6B | “PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B.” PMID 38824244 ↗ Jun 2024 |